Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Endoscopic Retrograde Cholangiopancreatography Access and Complication Rates After Cholecystectomy With Common Bile Duct Stones

8 giugno 2026 aggiornato da: Camilla Runfors, Karolinska Institutet

Complication Rates Associated With Access or Not to Endoscopic Retrograde Cholangiopancreatography (ERCP) in Units Performing Cholecystectomy, When Common Bile Duct Stones Are Detected on Intraoperative Cholangiography

The aim of this retrospective, register-based study is to investigate whether access, or no access, to endoscopic retrograde cholangiopancreatography (ERCP) at a surgical unit is associated with the risk of complications in patients undergoing laparoscopic cholecystectomy with common bile duct stones detected on intraoperative cholangiography.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Descrizione dettagliata

Annually, approximately 15,000 cholecystectomies are performed in Sweden. Cholecystectomy is indicated if gallstones cause recurrent biliary colic or complications. Gallstones can pass from the gallbladder into the common bile duct. Common bile duct stones (CBDS) can potentially cause biliary obstruction, cholangitis and pancreatitis.

Intraoperative cholangiography (IOC) during cholecystectomy is performed as a standard in Swedish surgical units. The arguments for routine IOC are several; routine IOC is associated with reduced risk of bile duct injury in patients with previous or ongoing cholecystitis, early detection of bile duct injury has been suggested to improve survival, and CBDS found by IOC, even small ones <4 mm, are associated with increased risk of complications and need for unplanned endoscopic retrograde cholangiopancreatography (ERCP) if no effort is made to clear the common bile duct.

American guidelines suggest performing IOC as a routine in adult patients undergoing laparoscopic cholecystectomy. Many countries do not practice routine IOC because it prolongs cholecystectomy and the evidence supporting its use is considered insufficient. European guidelines do not include routine IOC as a recommendation. On the other hand, both American and European guidelines advocate treatment of all CBDS, symptomatic or not.

CBDS represent a well-recognized clinical dilemma, especially when encountered first on IOC during cholecystectomy. In those situations, intraoperative treatment of CBDS has not been planned in advance.

There are several different approaches to remove CBDS. Worldwide, the two most common methods used are preoperative endoscopic retrograde cholangiopancreatography (ERCP) followed by cholecystectomy, or laparoscopic exploration of the common bile duct during cholecystectomy. In Sweden, the predominant treatment strategy for CBDS encountered on IOC is intraoperative ERCP.

The ERCP procedure itself is associated with a non-negligible risk of complications. The most common, and potentially severe, complication is post-ERCP pancreatitis (PEP). According to observational studies based on data from the Swedish Registry for Gallstone Surgery and ERCP (GallRiks), rendezvous-ERCP is associated with less complications, mainly PEP, compared to postoperative rendezvous-ERCP, and rendezvous-ERCP reduces the risk of PEP compared to conventional ERCP.

There are major differences between Swedish regions in the treatment of gallstone disease and outcome, probably because of different local routines. All units in Sweden performing cholecystectomies must be able to handle CBDS encountered at IOC, according to the national guidelines. The same guidelines advocate intraoperative ERCP with the rendezvous technique. ERCP volumes differ greatly between different surgical units in Sweden and the proportion of units performing ERCP has decreased over time. Smaller volumes of ERCP per surgeon are associated with more complications, including PEP.

In Sweden, part of the gallbladder surgery has moved from emergency care hospitals to elective, and sometimes private units, over the last few decades. Some of these units lack the equipment or expertise necessary for ERCP. Thus, despite what current national guidelines recommend, patients undergoing cholecystectomy, with a finding of CBDS on IOC, do not have the option to be treated with intra- or postoperative ERCP in such a surgical unit. Their CBDS must be treated in another way intraoperatively or with postponed ERCP after transfer to another unit.

How these structural differences in ERCP access at cholecystectomy affect the type of treatment of CBDS, time to treatment of CBDS, and thus complications, is not investigated. Because alternative treatment strategies to ERCP are used in units without access to ERCP, but also in units with access to ERCP, this question cannot simply be answered by the difference in complications from intra- and postoperative ERCP. Furthermore, these other strategies do not necessarily have a higher risk of complications compared to ERCP.

In a previous study, based on data from GallRiks, laparoscopic cholecystectomy with intraoperative rendezvous ERCP was associated with more complications compared to laparoscopic cholecystectomy with transcystic stent and postoperative ERCP.

The intention is to study how access to ERCP in different units affect complication rates in patients undergoing cholecystectomy when CBDS are detected on IOC. If the study shows no difference in risk of complications, there is a future possibility to transfer more gallbladder surgery out of emergency care hospitals and to enable more capacity for emergency surgery. On the other hand, if the study shows an increased risk of complications if the procedure is performed in a surgical unit without access to ERCP, there is an argument to transfer patients the other way around or establish capacity for ERCP at a greater number of hospitals.

Research question In patients undergoing laparoscopic cholecystectomy with CBDS on IOC, is there a difference in complication rates depending on access or not to ERCP at the surgical unit?

Aim and hypothesis The aim of this retrospective, register-based study is to investigate whether access, or no access, to ERCP at a surgical unit is associated with the risk of complications in patients undergoing laparoscopic cholecystectomy with CBDS detected on IOC.

The hypothesis is that laparoscopic cholecystectomy with CBDS on IOC in units with access to ERCP will be associated with less complications compared to units without access to ERCP.

PICO P Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with CBDS detected on IOC in Sweden 2015-2025 and registered in GallRiks.

I There is no specific intervention performed in each group. Instead, patients undergoing cholecystectomy at a unit without access to ERCP are considered as exposed individuals.

C Patients undergoing cholecystectomy at a unit with access to ERCP are considered unexposed, serving as controls.

O Primary outcome is complications within 30 days. Complications from both the cholecystectomy and the ERCP, if performed, will be considered since the entire course of care is important from a safety perspective.

Data will be analyzed separately for acute and elective gallbladder procedures, as units without access to ERCP perform elective surgery to a very large extent.

Sweden has a distinctive approach to manage CBDS, and a nationwide register for gallbladder surgery and ERCP, GallRiks. When validated, GallRiks has shown high completeness and high correctness of entered data. Taken together, this provides a unique possibility to contribute to research in gallbladder surgery.

Primary outcome Complications

Secondary outcomes Length of hospital stay, time from surgery to first treatment of common bile duct stones, unplanned ERCP after surgery due to CBDS, mortality

Tipo di studio

Osservativo

Iscrizione (Stimato)

10000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with common bile duct stones detected on intraoperative cholangiography in Sweden 2015-2025 and registered in GallRiks.

Descrizione

Inclusion Criteria:

  • ≥18 years old
  • Laparoscopic cholecystectomy with common bile duct stones (CBDS) detected on intraoperative cholangiography (IOC)
  • Procedure registered in the Swedish Registry for Gallstone Surgery and ERCP (GallRiks) 2015-2025

Exclusion Criteria:

  • Open surgery
  • Conversion to open surgery
  • Transgastric ERCP

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Cholecystectomy without access to endoscopic retrograde cholangiopancreatography (ERCP)
Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with CBDS detected on IOC in Sweden 2015-2025 and registered in GallRiks. The cholecystectomy is performed in a unit without access to ERCP.
The exposed group consists of patients undergoing laparoscopic and diagnosed with CBDS during cholecystectomy at a unit where ERCP is not available.
Cholecystectomy with access to ERCP
Patients, ≥18 years old, undergoing laparoscopic cholecystectomy with CBDS detected on IOC in Sweden 2015-2025 and registered in GallRiks. The cholecystectomy is performed in a unit with access to ERCP.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Complications
Lasso di tempo: 0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP
Overall complications from both the cholecystectomy and the endoscopic retrograde cholangiopancreatography (ERCP).
0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Length of hospital stay
Lasso di tempo: 0-100 days from the cholecystectomy, 0-100 days from any performed ERCP
Length of hospital stay for cholecystecomy plus ERCP
0-100 days from the cholecystectomy, 0-100 days from any performed ERCP
Time from cholecystectomy to first treatment of common bile duct stones
Lasso di tempo: 0-100 days from the cholecystectomy
Time from cholecystectomy to first treatment of common bile duct stones (days)
0-100 days from the cholecystectomy
Unplanned ERCP after surgery due to CBDS
Lasso di tempo: 1-365 days
Unplanned ERCP after treatment of CBDS
1-365 days
Unplanned readmission
Lasso di tempo: 0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP
Unplanned readmission (yes or no)
0- 30 days from the cholecystectomy, 0-30 days from any performed ERCP
Mortality
Lasso di tempo: 0-30 days from the cholecystectomy, 0-30 days from any performed ERCP
Mortality
0-30 days from the cholecystectomy, 0-30 days from any performed ERCP

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 ottobre 2026

Completamento dello studio (Stimato)

1 aprile 2029

Date di iscrizione allo studio

Primo inviato

21 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 giugno 2026

Primo Inserito (Effettivo)

10 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2026-02132-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Exposed group

Sottoscrivi